Dengue Virus: The time from the rainy season to the beginning of winter is considered the dengue season. During this time, a dengue outbreak is seen in the neighborhood. But now the dengue mosquito will not be able to bother you much. In fact, studies have revealed that the anti-dengue vaccine 'Qdenga' has shown more than 50 percent effect in reducing the cases of this disease and its effect remains for a long time.

This information has been obtained from a review of 19 studies. This is the first comprehensive review globally in which more than 20 thousand people were included. It has been found that after getting two doses of the vaccine, more than 90 percent of adults and children generated an immune response against all four types of dengue. Of these 19 studies analyzed, 13 had data from Asian and South American places where dengue is endemic. This vaccine was pre-approved by the World Health Organization in May.

Maria Elena Flacco, from the University of Ferrara in Italy and lead author of the study published in the journal Vaccine, said that given the results in terms of safety, immunogenicity, and efficacy, two doses can undoubtedly be an important tool for the prevention of dengue.

The 'Kudenga' vaccine,

also known as TAK-003, developed by Japan-based Takeda Pharmaceutical Industries Ltd., contains weakened versions of all four types of the DENV virus (dengue). The authors also found that more than 70 percent of adults and more than 90 percent of children and adolescents who received a single dose of the vaccine developed antibodies against the viral infection.

The authors said one study had a large enough sample size that spanned four and a half years and provided strong evidence of the long-term safety (and immunogenicity) of TAK-003.

Not yet approved in India

In February, Takeda and Hyderabad-based Biological E Ltd announced a strategic partnership to expand access to the 'Qdenga' vaccine. The vaccine has not yet been approved for use in India. The authors of the study said that the 'Qdenga vaccine has shown promising results, but a comprehensive estimate of its efficacy and safety is not available.